ESSA Pharma Inc. (NASDAQ:EPIX) Short Interest Update

ESSA Pharma Inc. (NASDAQ:EPIXGet Rating) (TSE:EPI) was the target of a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 1,890,000 shares, a growth of 81.7% from the March 15th total of 1,040,000 shares. Approximately 11.0% of the shares of the company are sold short. Based on an average daily trading volume, of 275,300 shares, the days-to-cover ratio is presently 6.9 days.

Several institutional investors have recently modified their holdings of the company. Bellevue Group AG boosted its position in shares of ESSA Pharma by 104.7% during the 3rd quarter. Bellevue Group AG now owns 5,034,814 shares of the company’s stock valued at $40,279,000 after acquiring an additional 2,575,000 shares in the last quarter. Soleus Capital Management L.P. lifted its holdings in ESSA Pharma by 22.9% during the 4th quarter. Soleus Capital Management L.P. now owns 3,525,457 shares of the company’s stock valued at $50,061,000 after purchasing an additional 657,434 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in ESSA Pharma by 72.4% during the 3rd quarter. Janus Henderson Group PLC now owns 3,477,844 shares of the company’s stock valued at $27,837,000 after purchasing an additional 1,459,950 shares during the last quarter. Eventide Asset Management LLC lifted its holdings in ESSA Pharma by 52.2% during the 4th quarter. Eventide Asset Management LLC now owns 3,318,647 shares of the company’s stock valued at $47,125,000 after purchasing an additional 1,137,546 shares during the last quarter. Finally, BVF Inc. IL lifted its holdings in ESSA Pharma by 16.3% during the 3rd quarter. BVF Inc. IL now owns 2,851,461 shares of the company’s stock valued at $22,812,000 after purchasing an additional 399,900 shares during the last quarter. Institutional investors and hedge funds own 89.80% of the company’s stock.

NASDAQ EPIX traded down $0.39 during midday trading on Friday, hitting $7.55. The company had a trading volume of 150,547 shares, compared to its average volume of 405,795. The firm has a fifty day simple moving average of $7.74 and a two-hundred day simple moving average of $9.79. ESSA Pharma has a fifty-two week low of $6.00 and a fifty-two week high of $36.00.

ESSA Pharma (NASDAQ:EPIXGet Rating) (TSE:EPI) last issued its earnings results on Thursday, February 3rd. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.02. As a group, sell-side analysts expect that ESSA Pharma will post -1.07 earnings per share for the current fiscal year.

ESSA Pharma Company Profile (Get Rating)

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer.

Featured Stories

Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.